FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3190859125> ?p ?o ?g. }

• W3190859125 abstract "Purpose: To examine the effect of medication sample use (ranibizumab or aflibercept) on future anti-vascular endothelial growth factor (VEGF) agent selection in neovascular age-related macular degeneration (nvAMD). Design: Retrospective cohort study. Methods: nvAMD patients who underwent an initial anti-VEGF injection with a sample medication were compared to nvAMD control patients who never received a medication sample. Charts from 2017 through 2020 were reviewed for data regarding demographics, anti-VEGF agent selection, and visual acuity outcomes for both groups. Anti-VEGF agent selection for the first four injections and at one year were examined in both the sample and control groups. Results: Adherence to the initial agent was high between first and subsequent injections (2nd, 3rd, 4th injection, and 1 year) in both sample (96.2%, 95.9%, 91.9%, 93.4%, respectively) and control groups (98.1%, 94.2%, 94.9%, 87.8%, respectively). Bevacizumab usage was significantly lower among eyes receiving samples relative to controls at the second (1.9% vs. 38.7%, p<0.001), third (3.1% vs. 41.3%, p<0.001), fourth injections (4.7% vs. 40.4%, p<0.001), and at 1 year (0% vs. 33.8%, p<0.001). Aflibercept usage was significantly higher in sample eyes relative to controls at the second (78.3% vs. 43.4%, p<0.001), third (76.3% vs. 41.5%, p<0.001), and fourth injections (76.7% vs. 43.4%, p<0.001), and at 1 year (77.0% vs. 52.7%, p<0.001). Conclusions: Eyes receiving a sample anti-VEGF agent (ranibizumab or aflibercept) for their initial injection were less likely to receive bevacizumab at future visits relative to eyes that did not receive an anti-VEGF sample, even after one year of treatment." @default.
• W3190859125 created "2021-08-16" @default.
• W3190859125 creator A5003464199 @default.
• W3190859125 creator A5006337681 @default.
• W3190859125 creator A5011881123 @default.
• W3190859125 creator A5017569999 @default.
• W3190859125 creator A5029270734 @default.
• W3190859125 creator A5035711783 @default.
• W3190859125 creator A5038698286 @default.
• W3190859125 creator A5042804572 @default.
• W3190859125 creator A5047246417 @default.
• W3190859125 creator A5050919831 @default.
• W3190859125 creator A5050971382 @default.
• W3190859125 creator A5051486317 @default.
• W3190859125 creator A5061294501 @default.
• W3190859125 creator A5066039903 @default.
• W3190859125 creator A5069463629 @default.
• W3190859125 creator A5069517897 @default.
• W3190859125 creator A5076751606 @default.
• W3190859125 creator A5085111515 @default.
• W3190859125 creator A5090613199 @default.
• W3190859125 date "2021-07-30" @default.
• W3190859125 modified "2023-10-18" @default.
• W3190859125 title "The effect of sample medication use on subsequent anti-VEGF agent selection for neovascular age-related macular degeneration" @default.
• W3190859125 cites W156473119 @default.
• W3190859125 cites W1960776002 @default.
• W3190859125 cites W1975926216 @default.
• W3190859125 cites W1987748266 @default.
• W3190859125 cites W2002892655 @default.
• W3190859125 cites W2044637793 @default.
• W3190859125 cites W2082732485 @default.
• W3190859125 cites W2090490740 @default.
• W3190859125 cites W2555189142 @default.
• W3190859125 cites W2956957447 @default.
• W3190859125 cites W3126876550 @default.
• W3190859125 doi "https://doi.org/10.1101/2021.07.27.21261104" @default.
• W3190859125 hasPublicationYear "2021" @default.
• W3190859125 type Work @default.
• W3190859125 sameAs 3190859125 @default.
• W3190859125 citedByCount "0" @default.
• W3190859125 crossrefType "posted-content" @default.
• W3190859125 hasAuthorship W3190859125A5003464199 @default.
• W3190859125 hasAuthorship W3190859125A5006337681 @default.
• W3190859125 hasAuthorship W3190859125A5011881123 @default.
• W3190859125 hasAuthorship W3190859125A5017569999 @default.
• W3190859125 hasAuthorship W3190859125A5029270734 @default.
• W3190859125 hasAuthorship W3190859125A5035711783 @default.
• W3190859125 hasAuthorship W3190859125A5038698286 @default.
• W3190859125 hasAuthorship W3190859125A5042804572 @default.
• W3190859125 hasAuthorship W3190859125A5047246417 @default.
• W3190859125 hasAuthorship W3190859125A5050919831 @default.
• W3190859125 hasAuthorship W3190859125A5050971382 @default.
• W3190859125 hasAuthorship W3190859125A5051486317 @default.
• W3190859125 hasAuthorship W3190859125A5061294501 @default.
• W3190859125 hasAuthorship W3190859125A5066039903 @default.
• W3190859125 hasAuthorship W3190859125A5069463629 @default.
• W3190859125 hasAuthorship W3190859125A5069517897 @default.
• W3190859125 hasAuthorship W3190859125A5076751606 @default.
• W3190859125 hasAuthorship W3190859125A5085111515 @default.
• W3190859125 hasAuthorship W3190859125A5090613199 @default.
• W3190859125 hasBestOaLocation W31908591251 @default.
• W3190859125 hasConcept C118487528 @default.
• W3190859125 hasConcept C126322002 @default.
• W3190859125 hasConcept C141071460 @default.
• W3190859125 hasConcept C144024400 @default.
• W3190859125 hasConcept C149923435 @default.
• W3190859125 hasConcept C167135981 @default.
• W3190859125 hasConcept C185592680 @default.
• W3190859125 hasConcept C2776403814 @default.
• W3190859125 hasConcept C2776694085 @default.
• W3190859125 hasConcept C2777802072 @default.
• W3190859125 hasConcept C2778257484 @default.
• W3190859125 hasConcept C2778749236 @default.
• W3190859125 hasConcept C2780084366 @default.
• W3190859125 hasConcept C2780699112 @default.
• W3190859125 hasConcept C2781100027 @default.
• W3190859125 hasConcept C3020157845 @default.
• W3190859125 hasConcept C31903555 @default.
• W3190859125 hasConcept C71924100 @default.
• W3190859125 hasConcept C72563966 @default.
• W3190859125 hasConceptScore W3190859125C118487528 @default.
• W3190859125 hasConceptScore W3190859125C126322002 @default.
• W3190859125 hasConceptScore W3190859125C141071460 @default.
• W3190859125 hasConceptScore W3190859125C144024400 @default.
• W3190859125 hasConceptScore W3190859125C149923435 @default.
• W3190859125 hasConceptScore W3190859125C167135981 @default.
• W3190859125 hasConceptScore W3190859125C185592680 @default.
• W3190859125 hasConceptScore W3190859125C2776403814 @default.
• W3190859125 hasConceptScore W3190859125C2776694085 @default.
• W3190859125 hasConceptScore W3190859125C2777802072 @default.
• W3190859125 hasConceptScore W3190859125C2778257484 @default.
• W3190859125 hasConceptScore W3190859125C2778749236 @default.
• W3190859125 hasConceptScore W3190859125C2780084366 @default.
• W3190859125 hasConceptScore W3190859125C2780699112 @default.
• W3190859125 hasConceptScore W3190859125C2781100027 @default.
• W3190859125 hasConceptScore W3190859125C3020157845 @default.
• W3190859125 hasConceptScore W3190859125C31903555 @default.
• W3190859125 hasConceptScore W3190859125C71924100 @default.
• W3190859125 hasConceptScore W3190859125C72563966 @default.
• W3190859125 hasLocation W31908591251 @default.

• next